source
- Biopharma M&A maintains strength even as large deals waneBiopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withstand an avalanche of major patent expiries. But there’s one notable missing piece: megad…Endpoints · 3mo ago↗ source
- Amgen expands crackdown on what it says is misuse of 340B programAmgen is expanding its claims data requirements for pharmacies dispensing its drugs under the 340B federal drug discount program. The company said the new policy addresses what it claims is fraud a…Endpoints · 3mo ago↗ source
- FDA hold puts Aardvark Prader-Willi drug in limboThe company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.BioPharma Dive